<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophr Bull</journal-id><journal-id journal-id-type="iso-abbrev">Schizophr Bull</journal-id><journal-id journal-id-type="publisher-id">schbul</journal-id><journal-title-group><journal-title>Schizophrenia Bulletin</journal-title></journal-title-group><issn pub-type="ppub">0586-7614</issn><issn pub-type="epub">1745-1701</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5888707</article-id><article-id pub-id-type="doi">10.1093/schbul/sby018.1011</article-id><article-id pub-id-type="publisher-id">sby018.1011</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Session III</subject></subj-group></subj-group></article-categories><title-group><article-title>S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Colizzi</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>McGuire</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Giampietro</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Brammer</surname><given-names>Mick</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Bhattacharyya</surname><given-names>Sagnik</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib></contrib-group><aff id="AF0001">Institute of Psychiatry, King&#x02019;s College</aff><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><pub-date iso-8601-date="2018-04-01" pub-type="epub"><day>01</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>44</volume><issue>Suppl 1</issue><issue-title>Abstracts for the Sixth Biennial SIRS Conference</issue-title><fpage>S413</fpage><lpage>S413</lpage><permissions><copyright-statement>&#x000a9; Maryland Psychiatric Research Center 2018.</copyright-statement><copyright-year>2018</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="sby018.1011.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Cannabis use can induce acute and long-lasting psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (&#x02212;)-trans-&#x00394;9-tetrahydrocannabinol (&#x02206;9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in modest cannabis users, who represent the majority of recreational users.</p></sec><sec id="s2"><title>Methods</title><p>Twenty-four healthy men participated in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject, &#x02206;9-THC challenge study.</p></sec><sec id="s3"><title>Results</title><p>Compared to non-users (N=12; &#x0003c;5 lifetime cannabis joints smoked), abstinent modest cannabis users (N=12; 24.5 &#x000b1; 9 lifetime cannabis joints smoked) showed worse performance and stronger right hemispheric activation during cognitive processing, independent of the acute challenge (all P&#x02264;0.047). Acute &#x02206;9-THC administration produced transient anxiety and psychotomimetic symptoms (all P&#x02264;0.02), the latter being greater in non-users compared to users (P=0.040). Non-users under placebo (control group) activated specific brain areas to perform the tasks, while deactivating others. An opposite pattern was found under acute (&#x02206;9-THC challenge in non-users) as well as residual (cannabis users under placebo) effect of &#x02206;9-THC. Under &#x02206;9-THC, cannabis users showed brain activity patterns intermediate between those in non-users under placebo (control group), and non-users under &#x02206;9-THC (acute effect) and cannabis users under placebo (residual effect). In non-users, the more severe the &#x02206;9-THC-induced psychotomimetic symptoms and cognitive impairments, the more pronounced was the neurophysiological alteration (all P&#x02264;0.036).</p></sec><sec id="s4"><title>Discussion</title><p>Previous modest cannabis use blunts the acute behavioral and neurophysiological effects of &#x02206;9-THC, which are more marked in people who have never used cannabis.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>